Sacubitril-Valsartan — Membership Pricing

Other medications in Heart & Cardiovascular

• Selexipag
• Sildenafil (PAH)
• Simvastatin
• Sotalol
• Tadalafil (PAH)
• Telmisartan
• Ticagrelor
• Torsemide

About Sacubitril-Valsartan

Sacubitril valsartan is a vital medication for many living with chronic heart failure, offering a significant improvement in quality of life and prognosis. At TheDrugClub, we understand the importance of affordable access to such critical treatments. Our members often find substantial savings on prescriptions like sacubitril valsartan, helping them manage their health without undue financial strain.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sacubitril-Valsartan is approved for (FDA label)

Sacubitril and valsartan tablets are a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

Source: Read the full FDA label on DailyMed. Label effective date: August 7, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Sacubitril-Valsartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue sacubitril and valsartan tablets as soon as possible ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue sacubitril and valsartan tablets as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 3173e592-6f28-4864-9bf0-0ef0452da3de. SPL document ID: 58755781-9a9f-4ab3-e063-6294a90aa226. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sacubitril-Valsartan (FDA label)

Sacubitril and valsartan tablets are supplied as unscored, ovaloid tablets in the following strengths: Sacubitril and Valsartan 24/26 mg, (sacubitril 24 mg and valsartan 26 mg) are white to off white in color, oval shaped tablets, debossed with 'V5' on one side and plain on other side. Sacubitril and Valsartan 49/51 mg, (sacubitril 49 mg and valsartan 51 mg) are light yellow to pale yellow in color, oval shaped tablets, debossed with 'V2' on one side and plain on other side. Sacubitril and Valsartan 97/103 mg, (sacubitril 97 mg and valsartan 103 mg) are light pink to pink in color, oval shaped tablets, debossed with 'V3' on one side and plain on other side.

Source: FDA prescribing information (DailyMed). Set ID: 3173e592-6f28-4864-9bf0-0ef0452da3de. SPL document ID: 58755781-9a9f-4ab3-e063-6294a90aa226. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sacubitril-Valsartan (FDA label)

Clinically significant adverse reactions that appear in other sections of the labeling include: Angioedema [see Warnings and Precautions (5.2) ] Hypotension [see Warnings and Precautions (5.3) ] Impaired Renal Function [see Warnings and Precautions (5.4) ] Hyperkalemia [see Warnings and Precautions (5.5) ] Adverse reactions occurring greater than or equal to 5% are hypotension, hyperkalemia, cough, dizziness, and renal failure. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Umedica Laboratories USA Inc. at 1-855-288-5777 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3173e592-6f28-4864-9bf0-0ef0452da3de. SPL document ID: 58755781-9a9f-4ab3-e063-6294a90aa226. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sacubitril-Valsartan (FDA label)

Sacubitril and valsartan tablets are contraindicated: in patients with hypersensitivity to any component in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2) ] with concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor [see Drug Interactions (7.1) ] with concomitant use of aliskiren in patients with diabetes [see Drug Interactions (7.1) ] Hypersensitivity to any component. ( 4 ) History of angioedema related to previous ACEi or ARB therapy. ( 4 ) Concomitant use with ACE inhibitors. ( 4 , 7.1 ) Concomitant use with aliskiren in patients with diabetes. ( 4 , 7.1 )

Source: FDA prescribing information (DailyMed). Set ID: 3173e592-6f28-4864-9bf0-0ef0452da3de. SPL document ID: 58755781-9a9f-4ab3-e063-6294a90aa226. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sacubitril-Valsartan (FDA label)

Observe for signs and symptoms of angioedema and hypotension. ( 5.2 , 5.3 ) Monitor renal function and potassium in susceptible patients. ( 5.4 , 5.5 ) 5.1 Fetal Toxicity Sacubitril and valsartan tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, consider alternative drug treatment and discontinue sacubitril and valsartan tablets.

Source: FDA prescribing information (DailyMed). Set ID: 3173e592-6f28-4864-9bf0-0ef0452da3de. SPL document ID: 58755781-9a9f-4ab3-e063-6294a90aa226. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sacubitril-Valsartan (FDA label)

Avoid concomitant use with aliskiren in patients with estimated glomerular filtration rate (eGFR) less than 60. ( 7.1 ) Potassium-sparing diuretics: May lead to increased serum potassium. ( 7.2 ) Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): May lead to increased risk of renal impairment. ( 7.3 ) Lithium: Increased risk of lithium toxicity. ( 7.4 ) 7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System Concomitant use of sacubitril and valsartan tablets with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4) ] . Avoid use of sacubitril and valsartan tablets with an ARB, because sacubitril and valsartan tablets contains the angiotensin II receptor blocker valsartan.

Source: FDA prescribing information (DailyMed). Set ID: 3173e592-6f28-4864-9bf0-0ef0452da3de. SPL document ID: 58755781-9a9f-4ab3-e063-6294a90aa226. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.